Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease
- Autori: Younes R.; Govaere O.; Petta S.; Miele L.; Tiniakos D.; Burt A.; David E.; Vecchio F.M.; Maggioni M.; Cabibi D.; Fracanzani A.L.; Rosso C.; Blanco M.J.G.; Armandi A.; Caviglia G.P.; Zaki M.Y.W.; Liguori A.; Francione P.; Pennisi G.; Grieco A.; Valenti L.; Anstee Q.M.; Bugianesi E.
- Anno di pubblicazione: 2020
- Tipologia: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/509998
Abstract
INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.